By RTT News, January 08, 2015, 07:02:00 AM EDT
The deal will grant Egalet exclusive worldwide rights to commercialize Acura’s immediate release oxycodone hydrochloride tablets product that incorporates Acura’s patented Aversion (abuse-deterrent) Technology platform.
The licensed product, formerly known as Oxecta, will be marketed by Egalet under the name Oxaydo. Oxaydo is FDA approved in 5mg and 7.5mg strengths for the treatment of acute and chronic moderate to severe pain.
The agreement provides for an upfront cash payment of $5 million to Acura upon execution, with an additional $2.5 million due upon the later of June 30, 2015, and the first commercial sale of the product in the U.S.; but in no event later than January 1, 2016.
For comments and feedback: contact firstname.lastname@example.org